ANAPTYSBIO, INC. Payments of Stock Issuance Costs
ANAPTYSBIO, INC. (ANAB) reported Payments of Stock Issuance Costs of $0 for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-09-21
- ANAPTYSBIO, INC. payments of stock issuance costs for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ANAPTYSBIO, INC. payments of stock issuance costs for the quarter ending 2024-12-31 was $122.00K.
- ANAPTYSBIO, INC. payments of stock issuance costs for the quarter ending 2023-12-31 was $0.00.
- ANAPTYSBIO, INC. payments of stock issuance costs for the quarter ending 2019-06-30 was $0.00.
- ANAPTYSBIO, INC. payments of stock issuance costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ANAPTYSBIO, INC. payments of stock issuance costs for fiscal 2024 was $492.00K.
- ANAPTYSBIO, INC. payments of stock issuance costs for fiscal 2023 was $0.00.
- ANAPTYSBIO, INC. payments of stock issuance costs for fiscal 2022 was $0.00.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-KT · filed 2026-09-21 | |||
| 2025-12-31 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $0.00 10-KT · filed 2026-09-21 | ||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-04 | |||
| 2024-12-31 | $122.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $492.00K 10-KT · filed 2026-09-21 | ||
| 2024-09-30 | $370.00K 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 10-K · filed 2026-03-03 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 | |||
| 2020-12-31 | $0.00 10-K · filed 2021-02-25 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-02-25 | |||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-07 | |||
| 2018-12-31 | $182.00K 10-K · filed 2021-02-25 | |||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $280.00K 10-Q · filed 2019-08-08 | $382.00K derived: sum of 3 quarters · filed 2020-03-02 | $394.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $280.00K 10-Q · filed 2019-05-07 | $382.00K derived: sum of 2 quarters · filed 2020-03-02 | $394.00K derived: sum of 3 quarters · filed 2020-03-02 | $1.48M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $102.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $114.00K derived: sum of 2 quarters · filed 2020-03-02 | $1.20M derived: sum of 3 quarters · filed 2020-03-02 | $1.60M 10-K · filed 2020-03-02 |
| 2017-09-30 | $12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $1.10M derived: sum of 2 quarters · filed 2018-08-07 | $1.50M 10-Q · filed 2017-11-07 | $1.59M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $1.49M 10-Q · filed 2018-08-07 | $1.58M derived: sum of 3 quarters · filed 2019-02-28 | $1.96M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $399.00K 10-Q · filed 2018-05-08 | $490.00K derived: sum of 2 quarters · filed 2019-02-28 | $876.00K derived: sum of 3 quarters · filed 2019-02-28 | $1.26M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $477.00K derived: sum of 2 quarters · filed 2019-02-28 | $864.00K derived: sum of 3 quarters · filed 2019-02-28 | $1.15M 10-K · filed 2019-02-28 |
| 2016-09-30 | $386.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $773.00K derived: sum of 2 quarters · filed 2017-11-07 | $1.06M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $387.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $670.00K 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | $283.00K 10-Q · filed 2017-05-12 | |||
| 2015-12-31 | $1.45M 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |